Form 10-K

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Snowflake, Chemours, and Evolv and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, April 8, 2024
Annual report, Ethics, CFO, Weapon, Risk, School, Air conditioning, Electronics, Snowflake Inc., News, Controller, Refrigeration, Form 10-K, IPO, Transport, Senior, SNOW, Complaint, Adjustment, P.C, Plastic, Audit committee, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • which lowered credit consumption.”  On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.
  • After the market closed on February 9, 2023, Chemours announced its fourth quarter and full year 2022 financial results.
  • For more information on the Evolv class action go to: https://bespc.com/cases/EVLV

Safe & Green Holdings Corp to Report Financial Results and File Its Form 10-K for the Year Ended December 31, 2023, on April 15, 2024

Retrieved on: 
Thursday, April 4, 2024
Form 10-K

Miami, FL, April 04, 2024 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures for residential, commercial, and point-of-care medicine, today announced that the Company has filed an extension and plans to report its financial results and file its Form 10-K for the year ended December 31, 2023, on April 15, 2024.

Key Points: 
  • Miami, FL, April 04, 2024 (GLOBE NEWSWIRE) -- Safe & Green Holdings Corp. (NASDAQ: SGBX Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures for residential, commercial, and point-of-care medicine, today announced that the Company has filed an extension and plans to report its financial results and file its Form 10-K for the year ended December 31, 2023, on April 15, 2024.
  • Paul Galvin, Chairperson and CEO of Safe and Green commented, “We are looking forward to providing our shareholders with a review of our results as well as a business update.”

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Retrieved on: 
Thursday, April 4, 2024
Bank statement, Annual report, Form 10-K, NESS, Security (finance)

CAMBRIDGE, Mass.

Key Points: 
  • CAMBRIDGE, Mass.
  • and NESS ZIONA, Israel, April 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2023, which was filed with the Securities and Exchange Commission on April 4, 2024, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm.
  • This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure of receipt of an audit opinion that contains a going concern qualification.
  • This announcement does not represent any change or amendment to the Company's 2023 audited financial statements or to its 2023 annual report on Form 10-K.

UMH PROPERTIES, INC. EXPANDS ITS EXISTING UNSECURED REVOLVING CREDIT AGREEMENT

Retrieved on: 
Wednesday, April 3, 2024
Facility, Annual report, Chase Bank, BMO, UMH Properties, Form 10-K, REIT, UMH, Wells Fargo, JPMorgan Chase

FREEHOLD, NJ, April 03, 2024 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE:UMH), announced today that it has expanded its existing unsecured revolving credit facility (the “Facility”) from $180 million in available borrowings to $260 million in available borrowings.

Key Points: 
  • FREEHOLD, NJ, April 03, 2024 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE:UMH), announced today that it has expanded its existing unsecured revolving credit facility (the “Facility”) from $180 million in available borrowings to $260 million in available borrowings.
  • These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina and Georgia.
  • UMH also has an ownership interest in and operates two communities in Florida, containing 363 sites, through its joint venture with Nuveen Real Estate.
  • The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Palo Alto Networks, Snowflake, Chemours, and Evolv and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, April 3, 2024
Transport, Form 10-K, P.C, Audit committee, Palo Alto Networks, Risk, PANW, Air conditioning, Electronics, Snowflake Inc., Annual report, Ethics, Federation, Defendant, News, Controller, Refrigeration, IPO, Senior, SNOW, Adjustment, Growth, CFO, Weapon, School, Complaint, Plastic, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the price of Palo Alto Networks, Inc. common stock declined by $104.12 per share, or approximately 28%, on February 21, 2024.
  • which lowered credit consumption.”  On this news, the price of Snowflake Class A common stock fell nearly 28% over several trading sessions, damaging investors.
  • For more information on the Evolv class action go to: https://bespc.com/cases/EVLV

VERB's MARKET.live Livestream Shopping Business Plan is Now Fully Funded

Retrieved on: 
Tuesday, April 2, 2024
LAS, LOS, Bank statement, VERB, Social media, History, Form 10-K

As further set forth in the Form 10-K, the Company disclosed that it had cash and cash equivalents of approximately $14.2 million and notes payable of approximately $1.2 million.

Key Points: 
  • As further set forth in the Form 10-K, the Company disclosed that it had cash and cash equivalents of approximately $14.2 million and notes payable of approximately $1.2 million.
  • This represents an increase in cash and cash equivalents of $10.9 million and a decrease in notes payable of approximately $7.3 million over the same period last year as previously disclosed in the Company’s 2022 Form 10-K filed on April 17, 2023.
  • As further stated in the current Form 10-K “[W]e believe that our enhanced cash position coupled with our substantially reduced current operating costs means our operations are fully funded for at least the next 14 months, and possibly longer subject to revenue generation during that period.
  • For more information, please visit MARKET.live or follow the latest updates on social media.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, April 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Kessler Topaz Meltzer & Check, LLP Notifies The Chemours Company Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Ethics, CC, CFO, District court, Lead, LLP, Controller, COPY, Form 10-K, Senior, Adjustment, Collection, Court, Audit committee, Cryptocurrency

RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).

Key Points: 
  • RADNOR, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company ( NYSE: CC ) (“Chemours” or the “Company”) on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”).
  • This action, captioned Taylor Jr. v. The Chemours Company, et al., Case No.
  • Important Deadline Reminder: Investors who purchased or otherwise acquired Chemours common stock during the Class Period may, no later than May 20, 2024, move the Court to serve as lead plaintiff for the class.
  • Kessler Topaz Meltzer & Check, LLP encourages Chemours investors who have suffered significant losses to contact the firm directly to acquire more information.

NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024

Retrieved on: 
Monday, April 1, 2024
Neuraxis, Form, PIN, Webcast, Calendar, Form 10-K, IPO

The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results.

Key Points: 
  • The Company has scheduled a conference call for the same day, Tuesday, April 9, 2024, at 4:30 pm ET to review the results.
  • Call-in Information: Interested parties can also access the live conference call by initially registering at the following link .
  • As indicated in this press release, the Company expects to have filed its Form 10-K on April 9, 2024.
  • The Company is unable to file timely due primarily to the unique circumstances associated with the Company’s IPO last year.

BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K

Retrieved on: 
Monday, April 1, 2024
Administration, Annual report, B cell, Obesity, Development, Cell, Patent, Library, Visual analogue scale, Patient, DSM-IV codes, Data monitoring committee, Form 10-K, Security (finance), Functional, Adipocyte, Type 2 diabetes, Small business, Investment, Research and development, NOA, European Patent Convention, Safety, Infrared spectroscopy correlation table, Orthopaedic Research Society, Annual general meeting, Pharmaceutical industry

MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.

Key Points: 
  • MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its Form 10-K annual report with the Securities and Exchange Commission ("SEC") for the year ended December 31, 2023.
  • The annual report can be accessed on the SEC's website at www.sec.gov , and on the Company's website at www.biorestorative.com under "SEC Filing" in the Investors and Media section.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • At December 31, 2023, BioRestorative had cash, cash equivalents and investments in marketable securities of $11.07 million.